tadalafil

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Erectile Dysfunction

Conditions

Erectile Dysfunction, Spinal Cord Injuries

Trial Timeline

Sep 1, 2004 → Jun 1, 2005

NCT ID

NCT00421083

About tadalafil

tadalafil is a phase 3 stage product being developed by Eli Lilly for Erectile Dysfunction. The current trial status is completed. This product is registered under clinical trial identifier NCT00421083. Target conditions include Erectile Dysfunction, Spinal Cord Injuries.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02252367	Approved	Completed	Dec 1, 2015	Jun 1, 2020	Prostatic Hyperplasia
NCT02224846	Approved	Completed	Oct 1, 2014	May 1, 2017	Erectile Dysfunction
NCT01326117	Approved	Withdrawn	Apr 1, 2011	Dec 1, 2013	Gastroparesis
NCT01324999	Phase 2/3	Completed	Mar 1, 2011	Oct 1, 2013	Pulmonary Hypertension
NCT01183650	Phase 1	Completed	Jul 1, 2010	Apr 1, 2011	Benign Prostatic Hyperplasia
NCT01066845	Pre-clinical	Completed	Jan 1, 2010	Aug 1, 2014	Pulmonary Arterial Hypertension
NCT00822354	Pre-clinical	Completed	Sep 1, 2008	Apr 1, 2010	Raynaud
NCT00157326	Phase 2	Completed	Sep 1, 2005	Jun 1, 2006	Hypertension
NCT00333281	Approved	Completed	Jun 1, 2005	Aug 1, 2006	Erectile Dysfunction
NCT00422578	Approved	Completed	Oct 1, 2004	Sep 1, 2005	Impotence
NCT00421083	Phase 3	Completed	Sep 1, 2004	Jun 1, 2005	Erectile Dysfunction
NCT00547417	Phase 3	Completed	Jul 1, 2003	Mar 1, 2004	Impotence
NCT00547599	Approved	Completed	Apr 1, 2003	Jan 1, 2004	Impotence

Competing Products

20 competing products in Erectile Dysfunction

See all competitors

Product	Company	Stage	Hype Score
tadalafil + placebo	Eli Lilly	Phase 3	77
YHD1023 + YHD1023 + YHD1023 + Cialis + Placebo	Yuhan	Phase 2	52
Tacrolimus + Placebo	Astellas Pharma	Approved	85
Mirabegron	Astellas Pharma	Phase 1/2	41
LY2452473 + Tadalafil + LY900010	Eli Lilly	Phase 1	33
tadalafil + placebo	Eli Lilly	Phase 3	77
LY2452473 + tadalafil + placebo (tadalafil) + placebo (LY2452473)	Eli Lilly	Phase 2	52
Tadalafil	Eli Lilly	Approved	85
tadalafil + placebo	Eli Lilly	Approved	85
Tadalafil + Sildenafil Citrate	Eli Lilly	Approved	85
Tadalafil + Placebo	Eli Lilly	Phase 3	77
Placebo + Tadalafil	Eli Lilly	Approved	85
Tadalafil + Placebo	Eli Lilly	Approved	85
tadalafil	Eli Lilly	Approved	85
Tadalafil + Sildenafil	Eli Lilly	Approved	85
tadalafil once a day [T(OaD)] + sildenafil citrate as needed [S(PRN)] + tadalafil as needed [T(PRN)]	Eli Lilly	Phase 3	77
Tadalafil + Placebo	Eli Lilly	Approved	85
Dapoxetine	Johnson & Johnson	Phase 3	77
dapoxetine	Johnson & Johnson	Phase 3	77
Placebo + Dapoxetine + PDE5I (phosphodiesterase-5 inhibitor)	Johnson & Johnson	Phase 3	77

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved